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COMMeNtary
T
his commentary discusses the con-
cept of β-cell dedifferentiation in 
diabetes, which is important but not well 
defined. A broad interpretation is that 
a state of differentiation has been lost, 
which means changes in gene expression 
as well as in structural and functional 
elements. Thus, a fully mature healthy 
β cell will have its unique differentiation 
characteristics, but maturing cells and old  
β cells will have different patterns of gene 
expression and might therefore be con-
sidered as dedifferentiated. The meaning 
of dedifferentiation is now being debated 
because β cells in the diabetic state lose 
components of their differentiated state, 
which results in severe dysfunction of 
insulin secretion. The major cause of this 
change is thought to be glucose toxicity 
(glucotoxicity) and that lowering glucose 
levels with treatment results in some res-
toration of function. An issue to be dis-
cussed is whether dedifferentiated β cells 
return to a multipotent precursor cell 
phenotype or whether they follow a dif-
ferent pathway of dedifferentiation.
Introduction
β-cell dedifferentiation is a term used 
to describe β cells with an altered pheno-
type that can lead to loss of key compo-
nents responsible for optimal performance 
including insulin secretion. This loss 
of critical β-cell machinery leads to the 
dysregulated insulin secretion that is a 
fundamental part of the pathogenesis of 
both types 1 and 2 diabetes (T1D and 
T2D).1 The word dedifferentiation has 
ambiguity because it means different 
things to different people (Fig. 1). Some 
see dedifferentiation as a change in β-cell 
phenotype that regresses back toward the 
multipotent progenitor cell from which it 
originated.2 However, one could also think 
of dedifferentiation as a loss of differenti-
ated components resulting in cells with 
little resemblance to primitive immature 
β cells or their precursors. β-cell hetero-
geneity should be part of this discussion 
because it must be accompanied by varia-
tions in gene expression. While these 
changes are likely be part of a normal life 
cycle or natural aging, it can be argued 
that these perhaps fluctuating changes 
could be considered modest alterations in 
dedifferentiation.
However dedifferentiation is defined, 
it is important because of its implica-
tions for β-cell function, birth, death, 
and regeneration, all of which contribute 
to the severity of the diabetic state. To 
appreciate the importance of differen-
tiation or the lack thereof, we will discuss 
the concepts of “functional β-cell mass,” 
β-cell maturation and heterogeneity, and 
finally the meaning and impact of a loss of 
differentiation.
Functional β-Cell Mass
Differentiation and dedifferentiation 
are important concepts for our under-
standing of “functional β-cell mass.” Beta 
cell mass is a simple concept, it is just the 
weight of all of the β cells in the pancreas, 
which is directly proportional to β-cell 
volume. It cannot be precisely correlated 
with  β-cell number because the size of 
individual β cells can vary.3 A key aspect 
of function is insulin secretion, which is 
more difficult to define as a number or 
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amount. One way to look at function 
is as glucose-stimulated insulin secre-
tion (GSIS), realizing that the amount 
of GSIS will of course depend upon the 
strength of the stimulus and the timing of 
the response. Insulin responses to a meal 
will have even more variable complexi-
ties. Because optimal insulin secretion is 
dependent upon the unique differentia-
tion of β cells, it is easy to see how loss or 
change of differentiation could result in 
impairment of insulin secretion in the 
absence of a change in β-cell mass, with 
the result being reduced functional β-cell 
mass.
Normal Differences in β-Cell 
Differentiation: β-Cell 
Maturation and Heterogeneity
Differentiation of β cells obviously 
changes as they develop from a multi-
potent precursor cell to full maturity.4,5 
This process has been best mapped out 
in rodents and it is noteworthy that full 
function in terms of the benchmark 
GSIS takes over a month after birth to 
develop.6 While a population of β cells 
in adulthood may look the same with 
insulin immunostaining or by change 
of a glucose-induced NAD(P)H auto-
fluorescence response during secretion,7 
there is certainly a great deal of hetero-
geneity. There are now many studies 
showing notable differences between 
single β cells in terms of secretion, gene 
expression, and cell size.8-11 The secretion 
differences have been particularly well 
demonstrated with the reverse hemolytic 
plaque assay.8 There must be a spectrum 
of change in β cells as they move from 
birth to death. β-cell biology would ben-
efit enormously if these different stages 
could somehow be identified by mark-
ers. The study of fetal and neonatal β 
cells has provided a lot of information 
about the major phenotypic changes 
that occur4,5 and markers of aging are 
also being found such as p16.12 There are 
other markers of aging that may prove 
valuable including senescence-associated 
β-galactosidase (SA-βgal)13 among oth-
ers.14,15 These differences are, however, 
only the tip of the iceberg; we look for-
ward to the identification of many more 
markers.
The adult pancreas provides even 
more examples of heterogeneity, which 
could be considered normal phenotypic 
variation (Fig. 1). A newly born β cell 
from neogenesis must have a very differ-
ent phenotype than a new β cell resulting 
from self-duplication. Another example 
is the recent finding of populations of 
less active islets that have low oxygen 
tension, less blood flow and presumably 
less insulin output.16 These might be 
considered “sleeping islets” because they 
can be awakened by increased demand 
for secretion as occurs in the pancreatic 
remnant left after partial pancreatectomy   
(PPx).
Glucotoxicity as a Cause of 
Dysfunctional Insulin Secretion
Almost 40 y ago, it was shown in 
humans that only a small increase of 
glucose levels was associated with a pro-
found loss of acute GSIS.17 Subjects with 
fasting glucose levels a little above 100 
mg/dl had reduced acute GSIS and once 
over 115 mg/dl the response was nil. This 
striking secretory defect, found when glu-
cose levels were short of being diagnostic 
for diabetes, has now been confirmed in 
humans and animals by many studies. 
Because this change of function was so 
tightly tied to rising glucose levels, we 
were attracted to the concept of what is 
now called glucotoxicity. β cells normally 
see glucose concentrations maintained 
within a very narrow range of about 
65–150 mg/dl, but when forced into an 
environment of even mild hyperglycemia 
their phenotype and function changes. 
To test this hypothesis we exposed β cells 
to hyperglycemia using several rat mod-
els including partial pancreatectomy,18 
glucose infusion19 and the neonatal strep-
tozocin,20 and found marked β-cell dys-
function, most notably with GSIS, in all 
cases. Coupling these findings with ear-
lier work looking at secretion changes in 
islets cultured in a high glucose environ-
ment, the glucotoxicity hypothesis was 
strengthened.21
Much has been written about lipotox-
icity and glucolipotoxicity also contribut-
ing to the secretory dysfunction found in 
diabetes.1 Unfortunately, almost all of the 
support for this hypothesis comes from in 
vitro experiments and as of yet there are 
no clearly convincing in vivo experiments 
showing that free fatty acid elevations in 
the pathophysiological range correlate 
with insulin secretory defects. As dis-
cussed in more detail elsewhere,1 our view 
is that there is no persuasive evidence that 
either lipotoxicity or glucolipotoxicity 
Figure 1. the differentiation state of a fully mature β cell can change with natural reversible events 
and during progression to death. the hyperglycemia of diabetes is thought to be the major deter-
minant causing β cells to lose their differentiation (also termed dedifferentiation), which leads to 
dysfunctional insulin secretion. this process is also called glucose toxicity, which can be at least 
partially reversed by treatment of hyperglycemia. an unanswered question is whether the β cells 
in the diabetes revert toward a multipotent precursor phenotype or a separate reversible dedif-
ferentiated state.www.landesbioscience.com Islets  235
acting through high free fatty acid lev-
els have adverse direct effects on β cells.1 
However, it is entirely possible that there 
are important derangements of lipid sig-
naling within β cells.
Dysfunction of insulin secretion is a 
major contributor to the hyperglycemia 
of diabetes.22 Studies looking at maximal 
stimulation in subjects with T2D and 
controls using glucose infusions followed 
by stimulation with arginine or isoproter-
enol found that the insulin response in 
T2D was only about 15% of that of the 
control.23,24 Because the average reduc-
tion in β-cell mass in T2D is about 50% 
of normal,25 it can be estimated that the 
secretory output of a given mass of β cells 
in the presence of hyperglycemia might 
be reduced to about 30% of normal. 
There is good reason to think that this 
loss of function is reversible because of 
the remarkable restoration of GSIS seen 
after bariatric surgery for T2D26 and the 
improvement of insulin secretion seen 
after intensive insulin treatment in a 
number of studies.27,28
β-Cell Dedifferentiation 
Following Surgical Reduction  
of β-Cell Mass
The rat partial pancreatectomy (PPx) 
model has proved particularly useful for 
studying changes in gene expression in 
β cells. After waiting 4 wk after surgery 
to minimize the confounding variables 
of early regeneration, islets were isolated 
from the remnant and studied for function 
and gene expression. These studies found 
gene expression changes that were similar 
to those found earlier in Zucker diabetic 
fatty rats.29 Among the notable findings 
in the PPx model was reduction in expres-
sion of genes that are normally highly 
expressed in β cells including insulin I and 
II, GLUT2, glucokinase, mitochondrial 
glycerol phosphate dehydrogenase, and 
pyruvate carboxylase.3,30 Conversely we 
found increased expression of genes that 
are normal poorly expressed in β cells, 
some of which are considered to be “dis-
allowed genes”31,32 including lactate dehy-
drogenase A and the monocarboxylic acid 
transporters, as well as glucose-6-phos-
phatase and hexokinase I. There was also 
reduced expression of transcription factors 
that maintain β-cell identity including 
MafA PDX-1, Nkx6.1, Pax6, HNF3b, 
HNF4a, and HNF1a.3,33 Another striking 
finding was a big increase in the expres-
sion of c-Myc, which may have contrib-
uted to β-cell phenotypic changes and the 
β-cell hypertrophy found in this model.
To show that these changes were not an 
artifact associated with surgery or regener-
ation, rats were kept normoglycemic with 
the administration of phlorizin during 
the last 2 wk of the 4-wk time period.3,30 
This largely prevented the changes pre-
sumably caused by hyperglycemia. None 
of the findings suggested that lipotoxicity 
was responsible for these changes, as there 
were no alterations in plasma triglycerides, 
non-esterified fatty acids, or islet triglyc-
eride levels.
The expression of many other genes 
were markedly changed in this model 
(some published, others not). These 
changes should receive more attention 
because they are associated with the 
marked dysfunction of insulin secretion, 
which is such an important concept for 
the pathophysiology and treatment of 
diabetes. A potentially important issue 
meriting mention concerns β cell suscep-
tibility to autoimmune killing in T1D. In 
the PPx model there were major changes 
in the expression of stress genes, death 
pathways and other genes that are likely 
to make the β cell a moving target for 
the immune system as blood glucose lev-
els climb.34 Differences in the expression 
of these genes in β cells as glucose levels 
move from normal to mild and then to 
severe hyperglycemia, may lead to changes 
in susceptibility to immune damage as 
disease progresses.
β-Cell Dedifferentiation Found 
with FoxO1 Knock Out
A mouse model developed by Talchai 
et al. is more complicated in that two 
major forces were influencing β cells: 
the direct effects of the FoxO1 knockout 
and secondary effects of hyperglycemia.2 
In contrast, when β-cell mass is reduced 
surgically as in the PPx model, the effects 
of hyperglycemia should be the dominant 
Figure 2. Baboons with chronic diabetes induced by streptozotocin were assessed for in vivo β-cell 
function, β-cell mass and insulin content after 5- 46 mo of diabetes.36 When pancreatic β-cell mass 
was 40–50% of that of the control animals, fasting hyperglycemia was present and accompanied 
by dysfunctional insulin secretion. pancreatic sections from 3 separate tissue blocks/ animal (5 
diabetic and 2 control animals; average of 60 ± 14 islets per section) were immunofluorescently 
stained for insulin (red) and a cocktail of antibodies against non-β-cell hormones (glucagon, soma-
tostatin, and pancreatic polypeptide) (green). the pancreatic cross sections were examined by 2 
blinded observers. this islet was from baboon after 34 mo of diabetes. all islet cells in all animals 
(control and with chronic diabetes) were immunostained for insulin, non-β-cell hormones or both. 
No “empty” cells could be identified.236  Islets  Volume 5 Issue 5
factor, without the added complexities 
inherent in models using β-cell toxins or 
genetic manipulation. The main findings 
of the FoxO1 knockout study were that 
there were changes of gene expression, 
some of which resembled those found in 
the PPx model. However, there were other 
findings either not found or not examined 
in the PPx model, most notably a popula-
tion of cells thought to be dedifferentiated 
β cells having no insulin by immunostain-
ing and expressing Neurogenin3, Oct4, 
Nanog and L-Myc. There was also some 
evidence that these dedifferentiated β 
cells can turn into α cells, as shown with 
lineage tracing. This led to the following 
provocative conclusion: “We propose that 
dedifferentiation trumps endocrine cell 
death in the natural history of beta cell 
failure and suggest that treatment of beta 
cell dysfunction should restore differen-
tiation, rather than promoting beta cell 
replication.” The main point that “treat-
ment… should restore differentiation” is 
in agreement with the conclusions of a lot 
of earlier work and our view is that this 
represents recovery from glucotoxicity as 
euglycemia is restored with treatment.
However, the following conclusions 
require scrutiny: “Dedifferentiated β cells 
reverted to progenitor like cells expressing 
Neurogenin3, Oct4, Nanog, and L-Myc. 
A subset of FoxO1-deficient beta cells 
adopted the alpha cell fate, resulting in 
hyperglucagonemia.” A key question is 
whether the changes in this FoxO1 mouse 
knockout can be found in human T2D. 
Detailed studies remain to be done but a 
recent report “did not detect any changes 
in Neurogenin3, Oct4, NANOG, or 
MYCL1 levels in human T2D islets”35.
The possible presence of “empty beta 
cells” containing no insulin is of consider-
able interest but key questions are whether 
insulin immunostaining could have been 
obtained by using a higher concentration 
of primary antibody. Then, if empty β 
cells can be found, how many are there 
and what contribution might they make? 
We have reexamined sections obtained 
from our PPx rats and a baboon model of 
T2D induced by streptozotocin, and in 
spite of the chronic hyperglycemia, can-
not find evidence for significant numbers 
of such “empty” cells but it is possible 
that a very small number might have been 
missed. A section of an islet from the dia-
betic baboon model (Fig. 2) is an example 
of our failure to find such cells36; details 
of the study are provided in the legend.
Questions must also be asked about 
how many α cells might have been gener-
ated form these dedifferentiated β cells. 
The presence of hyperglucagonemia is 
universally found in the diabetic state so 
it is difficult to attribute this to secreted 
glucagon from new α cells.
Summary
Altered  β-cell differentiation asso-
ciated with diabetes is now receiving a 
great deal of attention. The changes in 
β-cell phenotype are marked and are no 
doubt largely responsible for the impaired 
insulin secretion in T2D and the early 
stages of T1D. The changes are linked 
to and probably caused by hyperglycemia 
and there are good reasons to think that 
obtaining euglycemia with treatment will 
restore the normal phenotype of these β 
cells (Fig. 1). It is reasonable to use the 
term dedifferentiation to describe a loss 
of differentiated features. Some of these 
changes can be viewed as a move toward 
a more primitive state, but questions 
remain as to whether they can revert to 
true multipotent precursor cells and if 
so, what are the prospects for significant 
regeneration from whatever number of 
these cells might be present? We look for-
ward to these questions being answered in 
the near future.
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